Patient dosing has concluded for the second and last cohort of the pharmacokinetics study of AD04 Topline results expected during the fourth quarter GLEN ALLEN, Va., Aug. 07, 2024 (GLOBE NEWSWIRE) -- Adial Pharmaceuticals, Inc. (NASDAQ:ADIL) ("Adial" or the "Company"), a clinical-stage biopharmaceutical company focused on developing therapies for the treatment and prevention of addiction and related disorders, announced that the final patient has completed the last dose in the pharmacokinetics study of AD04 ...